- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00532415
Safety and Efficacy of Vitreous Delineating Agent During Vitrectomy
April 3, 2012 updated by: Alcon Research
Clinical Evaluation of the Safety and Efficacy of Triamcinolone Acetonide Suspension for Visualization During Vitrectomy Surgery
The purpose of this study is to evaluate the safety and efficacy of triamcinolone acetonide suspension when used for visualization of structures in the back of the eye during eye surgery.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients planning to undergo pars plana vitrectomy with good vision in the non-surgery eye.
- Other protocol-defined inclusion criteria may apply.
Exclusion Criteria:
- Patients under 18.
- Patients with previous vitrectomy, elevated intraocular pressure (IOP) and/or history of ocular inflammatory disease.
- Other protocol-defined exclusion criteria may apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Triamcinolone
Approximately 1-4 mg (0.025-0.1 cc) as needed for visualization during pars plana vitrectomy with or without membrane removal.
|
Approximately 1-4 mg (0.025-0.1 cc) as needed for visualization during pars plana vitrectomy with or without membrane removal.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Mean Visualization Score at Post-Instillation from Pre-Instillation
Time Frame: Day 0
|
A video image of the posterior segment structures of the eye was taken before instillation of the test product and after.
An independent masked reader evaluated the images and graded the degree of visualization on a 5-point scale ranging from 1 to 4 and anchored at the ends by "Not Visible (0)" and "Clearly Delineated (4)."
The mean difference was calculated, and a higher number indicated increased visibility.
|
Day 0
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2007
Primary Completion (Actual)
September 1, 2007
Study Completion (Actual)
September 1, 2007
Study Registration Dates
First Submitted
September 19, 2007
First Submitted That Met QC Criteria
September 19, 2007
First Posted (Estimate)
September 20, 2007
Study Record Updates
Last Update Posted (Estimate)
April 5, 2012
Last Update Submitted That Met QC Criteria
April 3, 2012
Last Verified
April 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Immunosuppressive Agents
- Immunologic Factors
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Triamcinolone
- Triamcinolone Acetonide
- Triamcinolone hexacetonide
- Triamcinolone diacetate
Other Study ID Numbers
- C-05-62
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vitrectomy
-
VISTA OphthalmicsCBCC Global ResearchActive, not recruitingVitrectomyUnited States
-
ThromboGenicsCompletedVitrectomyUnited States
-
Asociación para Evitar la Ceguera en MéxicoUnknown
-
Innovative MedicalCompletedVitrectomyUnited States
-
Vanderbilt University Medical CenterAlcon ResearchCompleted
-
ThromboGenicsCompleted
-
Universitaire Ziekenhuizen KU LeuvenTerminated
-
AllerganCompletedVitrectomyUnited States, Czech Republic
-
Kocaeli UniversityCompleted
-
Eyegate Pharmaceuticals, Inc.Completed
Clinical Trials on Triamcinolone Acetonide Injectable Suspension
-
University of North Carolina, Chapel HillFlexion Therapeutics, Inc.Completed
-
Weill Medical College of Cornell UniversityCompletedNail Diseases | Nail PsoriasisUnited States
-
University of VirginiaRecruitingAdhesive Capsulitis of Shoulder | Adhesive Capsulitis | Frozen ShoulderUnited States
-
ROC FoundationCompletedOsteoarthritis, KneeUnited States
-
Marie BadalamenteRecruitingCarpometacarpal (CMC) OsteoarthritisUnited States
-
The Cleveland ClinicArthritis FoundationEnrolling by invitationOsteoarthritis, Knee | Meniscus; Degeneration | Synovitis | Meniscus TearUnited States
-
Cale JacobsVanderbilt UniversityCompleted
-
Sunnybrook Health Sciences CentreRecruitingGlaucoma | Choroidal EffusionsCanada
-
Wills EyeAlcon ResearchCompleted
-
Pacira Pharmaceuticals, IncTerminatedPost-traumatic Osteoarthritis of the KneeUnited States